A clinical-stage biotechnology company developing antiviral and oncology therapies for serious diseases with limited treatment options. Its pipeline includes small‑molecule drugs targeting rare cancers and viral infections, with value largely tied to clinical trial outcomes and regulatory decisions....
1 member of Congress has disclosed 1 trade in Chimerix Corporation (CMRX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-01-14 | JAMES B. RENACCI | buy | $15K – $50K |